<DOC>
	<DOCNO>NCT01478347</DOCNO>
	<brief_summary>The propose study evaluate safety rMenB+OMV NZ adult population potentially risk meningococcal disease ( e.g . lab worker ) . In second part study additional blood sample high respond vaccinated subject collect purpose generate control serum panel human serum bactericidal assay ( hSBA ) test .</brief_summary>
	<brief_title>A Phase 3b Study Assess Safety Novartis Meningococcal B Recombinant Vaccine When Administered Healthy At-risk Adults</brief_title>
	<detailed_description />
	<mesh_term>Meningitis</mesh_term>
	<mesh_term>Meningococcal Infections</mesh_term>
	<mesh_term>Meningitis , Meningococcal</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Inclusion criterion : 1 . 18 65 year age inclusive give write informed consent time enrollment ; 2 . Able comprehend follow require study procedure ; 3. Who available visit schedule study ( i.e. , plan leave area end study period ) ; 4 . In good health determine outcome medical history , physical examination clinical judgment investigator ; 5. Who might routinely expose N. meningitidis culture Inclusion criterion protocol part 2 1 . 18 65 year age inclusive ; 2 . At least 50 kg weight ; 3 . Blood pressure within follow range : Systolic 110180 ; Diastolic 60100 ; 4 . Regular pulse rate ( 5090 beat per minute ) exception acceptable upon investigator 's judgment ; 5 . Hematocrit high : 32 % woman 35 % male ; 6 . Visit 3 serum suitable control standardization SBA confirm central laboratory . Exclusion criterion : 1 . History serogroup B meningococcal vaccine administration 2 . History severe allergic reaction previous vaccination hypersensitivity vaccine component ; 3 . Pregnancy nursing ( breastfeed ) mother ; 4 . Females childbearing age use plan use acceptable birth control measure , duration study . Oral , inject implanted hormonal contraceptive , barrier method ( condom diaphragm spermicide ) , intrauterine device , surgical sterilization , transdermal delivery , congenital sterility sexual abstinence consider acceptable form birth control . If sexually active subject must use one accepted birth control method least one month prior study entry ; 5 . Known suspected autoimmune disease impairment/alteration immune system result ( example ) : 6 . Receipt chronic immunosuppressive therapy 7 . Receipt chronic immunostimulants 8 . Immune deficiency disorder , know HIV infection 9 . Known bleed diathesis condition may associate prolonged bleeding time . 10 . History illness/condition , opinion investigator , might interfere evaluation study objective pose additional risk subject due participation study . 11 . Any significant chronic infection . 12 . Any serious chronic progressive disease accord judgment investigator ( e.g . neoplasm , insulin dependent diabetes , cardiac , renal hepatic disease ) . Exclusion criterion protocol part 2 : 1 . Known suspected autoimmune disease ; 2 . Any serious chronic progressive disease accord judgment investigator ( e.g . neoplasm , diabetes , cardiovascular , renal , hepatic , immunological , metabolic , urogenital , hematological , gastrointestinal , central nervous system disease ) ; 3 . Known bleed diathesis condition may associate prolonged bleeding time ; 4 . History fainting seizure episodes ; 5 . Pregnancy 6 . Any significant chronic infection ; 7 . Significant acute infection within previous 2 week ; 8 . Known suspected autoimmune disease impairment/alteration immune system result ( example ) : Receipt chronic immunosuppressive therapy ; Receipt chronic immunostimulants ; Immune deficiency disorder , know HIV infection ; 9 . Significant acute illness within previous 7 day body temperature 38.0 C within previous 3 day ; 10 . Receipt systemic antibiotic within previous 3 day ( 72 hour ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Neisseria , Meningitis , Group B , Vaccine , At-risk , Adults</keyword>
</DOC>